These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Precise therapy for lung cancer patients with rare sensitive mutations of epidermal growth factor receptor]. Li Y; Chen LA Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):881-884. PubMed ID: 29262502 [TBL] [Abstract][Full Text] [Related]
23. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Kobayashi IS; Viray H; Rangachari D; Kobayashi SS; Costa DB Cells; 2021 Dec; 10(12):. PubMed ID: 34944068 [No Abstract] [Full Text] [Related]
24. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Gallant JN; Sheehan JH; Shaver TM; Bailey M; Lipson D; Chandramohan R; Red Brewer M; York SJ; Kris MG; Pietenpol JA; Ladanyi M; Miller VA; Ali SM; Meiler J; Lovly CM Cancer Discov; 2015 Nov; 5(11):1155-63. PubMed ID: 26286086 [TBL] [Abstract][Full Text] [Related]
25. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844 [TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073 [TBL] [Abstract][Full Text] [Related]
28. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398 [TBL] [Abstract][Full Text] [Related]
29. Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer. Wang DD; Lee VH; Zhu G; Zou B; Ma L; Yan H Mol Biosyst; 2016 Apr; 12(5):1552-63. PubMed ID: 26961138 [TBL] [Abstract][Full Text] [Related]
30. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664 [TBL] [Abstract][Full Text] [Related]
31. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors. Shaffer W; Kobayashi IS; Sentana-Lledo D; Sundararaman S; Lee MD; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB Lung Cancer; 2023 Jul; 181():107250. PubMed ID: 37196448 [TBL] [Abstract][Full Text] [Related]
32. The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations. Taniguchi Y; Matsumoto Y; Furukawa R; Ohara S; Usui K Int J Clin Oncol; 2018 Jun; 23(3):452-457. PubMed ID: 29446042 [TBL] [Abstract][Full Text] [Related]
33. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Kobayashi Y; Mitsudomi T Cancer Sci; 2016 Sep; 107(9):1179-86. PubMed ID: 27323238 [TBL] [Abstract][Full Text] [Related]
34. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Marquez-Medina D; Popat S Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834 [TBL] [Abstract][Full Text] [Related]